Dr. Barry Dworkin

New insights into how prostate cancer protects itself from latest therapies after researchers uncover the gene responsible for this resistance while investigating new drug that circumvents these protective mechanisms.

Medical Mythbusting Commentary for November 28, 2022

[display_podcast]

Source:
Drug triggers immune cells to attack prostate cancer

Reference:
Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance.

Related posts:

  1. Genes research offers cancer treatment hope
  2. Prostate cancer surgery results no different from not doing the surgery: study
  3. Genetic test for prostate cancer recurrence can help personalize care and management
  4. McGill University study shows that a shortened course of radiation therapy is safe and effective for men with high-risk prostate cancer